Immutep Ltd ADR (IMMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immutep Ltd ADR (IMMP) has a cash flow conversion efficiency ratio of -0.284x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.12 Million) by net assets ($98.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Immutep Ltd ADR to measure how many days the company can operate on defensive assets alone.
Immutep Ltd ADR - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Immutep Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immutep Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Phillips 66
F:PSX
|
0.024x |
|
Neuronetics Inc
NASDAQ:STIM
|
-0.552x |
|
Daehan Synthet
KO:003830
|
-0.005x |
|
Gowing Bros Ltd
AU:GOW
|
-0.003x |
|
Hanil Iron & S
KO:002220
|
-0.029x |
|
Dual Co Ltd
KO:016740
|
0.028x |
|
Nova Minerals Limited
NYSE MKT:NVA
|
0.066x |
|
Drilling Tools International Corp.
NASDAQ:DTI
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Immutep Ltd ADR (2008–2025)
The table below shows the annual cash flow conversion efficiency of Immutep Ltd ADR from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Immutep Ltd ADR (IMMP) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $143.64 Million | $-62.05 Million | -0.432x | -135.12% |
| 2024-06-30 | $189.52 Million | $-34.82 Million | -0.184x | +30.12% |
| 2023-06-30 | $136.47 Million | $-35.88 Million | -0.263x | +18.17% |
| 2022-06-30 | $94.08 Million | $-30.23 Million | -0.321x | -33.47% |
| 2021-06-30 | $73.27 Million | $-17.64 Million | -0.241x | +26.04% |
| 2020-06-30 | $33.30 Million | $-10.84 Million | -0.326x | +48.07% |
| 2019-06-30 | $24.39 Million | $-15.29 Million | -0.627x | -170.19% |
| 2018-06-30 | $33.52 Million | $-7.78 Million | -0.232x | +27.64% |
| 2017-06-30 | $26.53 Million | $-8.51 Million | -0.321x | -0.12% |
| 2016-06-30 | $35.32 Million | $-11.31 Million | -0.320x | -1.53% |
| 2015-06-30 | $24.69 Million | $-7.79 Million | -0.315x | +49.92% |
| 2014-06-30 | $22.59 Million | $-14.23 Million | -0.630x | -14.85% |
| 2013-06-30 | $29.25 Million | $-16.04 Million | -0.548x | -6.56% |
| 2012-06-30 | $37.16 Million | $-19.12 Million | -0.515x | -190.62% |
| 2011-06-30 | $55.10 Million | $-9.76 Million | -0.177x | +54.00% |
| 2010-06-30 | $16.79 Million | $-6.46 Million | -0.385x | +62.96% |
| 2009-06-30 | $1.81 Million | $-1.88 Million | -1.039x | -76.06% |
| 2008-06-30 | $2.63 Million | $-1.55 Million | -0.590x | -- |
About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more